


Less doubt, more confidence



Lunit INSIGHT Breast Suite* is an advanced clinically proven AI solution that rapidly and accurately identifies suspicious abnormalities and lesions in mammograms. Available for both 2D and 3D imaging, Lunit INSIGHT boosts radiologists' confidence in ruling out normal cases, minimizing time spent on false positives. This allows greater focus on high-priority, suspicious cases and supports earlier cancer detection, even in dense breast tissue. With Lunit, radiologists can work more efficiently and confidently, leading to improved patient outcomes.

1. Superior performance

- Head-to-head comparison of three vendors in JAMA oncology: Lunit superior in sensitivity/specificity¹
- Trained on a large, curated data set of 3.3M+ images
 - >30% positive cancer cases
 - Biopsy ground truth for higher accuracy
 - 70% dense breasts cases
 - U.S., U.K., and Korean patient data for less bias in outcomes


2. Workflow advantages

- Control of when to read complex cases
- Click and jump to the DBT slide you need
- Integration with Volpara Scorecard™

*Available in select countries

3. How it works


- Abnormality Scoring
- Each lesion ranked from 0-100
- Stronger cancer prediction, higher score
- Scores indicate AI confidence level not severity
- Visible but not suspicious lesions are not marked




“Our research found Lunit AI could reduce interval breast cancers by more than one-third.”

Manisha Bahl
MD, MPH, FSBI, Massachusetts General Hospital

AI you'll love, performance you can trust



Clinical Research Highlights



Detect cancers earlier²

“Lunit provides peace and confidence reading each case. It has especially been helpful in spotting clustered pleomorphic calcifications which can be very difficult to detect with DBT. Anyone who wants security or is less experienced will benefit from using Lunit AI.”

David Forsberg, MD, Breast Radiologist, Mosaic Breast Imaging

Empower general radiologists³


“Adding Lunit AI as an assistant can improve the performance of general radiologists almost equivalent to the breast-trained radiologist.”

Niketa Chotai, MD, Breast Radiologist, RadLink


First AI deployed as independent reader in double reading setting : 1-year post-implementation results

Increased Diagnostic Performance


+15%
Cancer Detection Rate



-11%
Recall Rate



+31%
PPV




Reduced Waiting Times

“With AI, I now read less normal cases and focus on more advanced exams.”

Without AI, the waiting time for a clinical mammogram was around 5 to 6 weeks. Now it's down to zero.”

Dr. Karin Dembrower



Experienced Benefits

Improved diagnostic performance:

- More cancers detected early
- Fewer unnecessary recalls, reducing stress for patients
- No more screening waiting time

Enhanced radiologist efficiency:

- Less time spent on routine mammogram screenings
- More time to focus on complex, higher-value work

References: 1 Salim M et al. External evaluation of 3 commercial AI Algorithms for independent assessment of screening mammograms. *JAMA Oncology*. 2020; 6(10):1581 - 1588.
/ 2,3 Kim, Hyo-Eun et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. *The Lancet Digital Health*, Volume 2, Issue 3, Mar 2020. / 4 Dembrower, Karin et al. Artificial Intelligence for Breast Cancer Detection in screening mammography in Sweden: A prospective, population-based, paired-reader, non-inferiority study. *The Lancet Digital Health*, vol 9(10), pg E703-E711, Sept 2023 / 5 Eun Kyung Park, et al., Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time. *Radiology Artificial Intelligence*, 2024 / 6 Lee, Si Eun, et al., Comparison of conventional CAD and AI-CAD applied to digital mammography in respect of false-positive marks. *Journal of the Korean Society for Breast Screening*, 2020 / 7 Eun Kyung Park, et al., Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time. *Radiology Artificial Intelligence*, 2024

*Lunit INSIGHT Breast Suite refers to two of Lunit's flagship products, Lunit INSIGHT MMG and Lunit INSIGHT DBT.

INSIGHT DBT and MMG software is currently under reclassification review by the TGA. Until this process is complete, new license delivery is limited to investigational use only in Australia. Existing customers remain unaffected. The software is CE marked. FDA cleared and remains available to all other countries.

CE Certified (MDR (EU) 2017/745) *FDA Cleared (excluding certain features – contact your local Lunit representative for more details) Lunit INSIGHT MMG is a Computer-Assisted Detection/Diagnosis (CADe/x) software for diagnosis of areas suspicious for breast cancer in mammograms. The device is an auxiliary detection and diagnosis aid, not an interpretive nor diagnostic aid. It should be used only after the first reading by interpreting physicians. Lunit INSIGHT DBT is a computer-assisted detection and diagnosis (CADe/x) software intended to be used concurrently by interpreting physicians to aid in the detection and characterization of suspicious lesions for breast cancer in digital breast tomosynthesis (DBT) exams. The device is an auxiliary detection and diagnosis aid, not an interpretive nor diagnostic aid. It should be used only after the first reading by interpreting physicians. This document is for use by healthcare professionals only. The radiologist should always rely on his or her own clinical and professional opinion whether to use a certain product to diagnose or treat a patient. Not all Lunit products may be available in all markets, as availability is based on the medical and/or regulatory practices of each market. Contact your Lunit representative if you have questions about the availability of the Lunit products in your area.

Lunit, Inc. owns, uses or enforces the following trademarks of service marks: Lunit, Lunit INSIGHT MMG, and Lunit INSIGHT DBT. The products described are CE certified in accordance with applicable EU standards and regulations. The product fulfills the requirements for CE certification. 5F, 374 Gangnam-daero, Gangnam-gu, Seoul, 06241, Republic of Korea

